Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Cash from Financing Activities data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 300.0% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 137.33% YoY) and the FY2025 annual result came in at -$300000.0, down 105.26% from the prior year.
• Cash from Financing Activities slipped to -$1.2 million in Q1 2026, from -$600000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $790.0 million in Q2 2023 to a low of -$1.2 million in Q1 2026.
• A 5-year average of $69.0 million and a median of $670000.0 in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 78200.1% in 2023, down 1876.0% in 2023.
• Tracing LEGN's Cash from Financing Activities over 5 years: stood at -$783000.0 in 2022, then surged by 218.14% to $925000.0 in 2023, then plunged by 132.43% to -$300000.0 in 2024, then sank by 100.0% to -$600000.0 in 2025, then sank by 100.0% to -$1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.2 million (Q1 2026), -$600000.0 (Q4 2025), and $670000.0 (Q3 2025), per Business Quant data.